ADVFN - Advanced Financial Network.
HOME» NASDAQ » A » AMGN Stock Price » AMGN Stock News

Amgen Inc. Share News

 Amgen Inc. (mm) Stock Price
AMGN Stock Price
 Amgen Inc. (mm) Stock Chart
AMGN Stock Chart
 Amgen Inc. (mm) Stock News
AMGN Stock News
 Amgen Inc. (mm) Company Information
AMGN Company Information
 Amgen Inc. (mm) Stock Trades
AMGN Stock Trades

Bayer To Develop Cancer Treatment With Amgen

FRANKFURT -(Dow Jones)- German chemical and pharmaceutical company Bayer AG (BAYN.XE) said Tuesday it has agreed with Amgen Inc. (AMGN) to develop and commercialize a new antibody for treating cancer. MAIN FACTS: -Financial details of the deal weren't disclosed. -Bayer will collaborate with Amgen at its Munich site from the research phase to the completion of initial clinical trials. -After the initial trials have been completed, Bayer will be responsible for further development and commercialization of the product candidate. -In 2009, Bayer had entered into an agreement with Micromet, Inc. to produce another antibody. -Micromet was acquired by Amgen in early 2012. -Frankfurt Bureau, Dow Jones Newswires; 49-69-29725-500

Stock News for Amgen Inc. (AMGN)
DateTimeHeadline
02/10/201610:17:35Amended Statement of Ownership (sc 13g/a)
02/09/201618:20:00Panel Recommends FDA Approval of Remicade Knockoff
02/09/201618:16:00Panel Recommends FDA Approval of Remicade Knockoff
02/07/201618:15:00Drug Industry Launches Ad Campaign Aimed at Lawmakers
02/05/201617:06:00Amgen To Present At The Leerink Partners 5th Annual Global Healthcare...
02/04/201616:17:00Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint...
02/04/201616:00:00Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3...
01/28/201616:40:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/28/201616:31:00Amgen Profit Rises 39%; 2016 Outlook Raised
01/28/201616:00:00Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And...
01/25/201617:20:00FDA Accepts Amgen's Biosimilar Biologics License Application...
01/25/201616:03:00Amgen Announces Webcast of 2015 Fourth Quarter and Full Year...
01/23/201613:00:00Vectibix® (panitumumab) And Best Supportive Care Improves Overall...
01/22/201601:00:00Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor...
01/21/201616:32:00FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy...
01/11/201612:50:00Celgene Names New CEO, Cuts 2015 Profit Outlook
01/10/201620:33:00Drugmakers Keep Raising Prices Despite Criticisms
01/07/201616:05:00Amgen To Present At The 34th Annual J.P. Morgan Healthcare Conference
12/18/201501:00:00European Commission Approves Amgen's IMLYGIC™ (talimogene laherparepvec) A...
12/15/201516:45:00Amgen Raises Quarterly Dividend 27%

Amgen Inc. and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad